Umoja Biopharma plans for the construction of a new state-of-the-art laboratory and innovative manufacturing facility in Colourado, USA.
The facility is designed to accelerate therapeutic candidate development.
The first phase covers 77,000 square feet, housing cutting-edge labs, offices, and manufacturing areas tailored for lentiviral vector production.
This space is designed with the flexibility to expand to 146,000 square feet, aligning seamlessly with anticipated future supply requirements.
The opening of this facility will support the development and commercialisation of gene therapies that can scale effectively by creating a significant and meaningful impact on the lives of patients globally.
This facility is set to drive in-house tech development, guarantee top-notch quality for clinical trials, and establish a robust, adaptable supply chain foundation.
The laboratory & innovative manufacturing building is is projected for the first quarter of 2024.
Name Umoja Biopharma
Type New Construction